Market Research Future/MRFR expects the Rheumatoid Arthritis Market to perform significantly between 2020 and 2027, which is the review period.

Top Boosters and Barriers

Rapidly escalating cases of rheumatoid arthritis worldwide combined with the expanding geriatric populace highly prone to various ailments benefit the global market. The Centers for Disease Control and Prevention confirms that the in the year 2017, close to 54.4 million Americans suffered from arthritis, which forms nearly 25% of the total population. Out of this, roughly 1.3 million patients were affected by rheumatoid arthritis.

Apart from this, soaring demand for biologics and the growing prevalence of generic drugs also add to the market value. Another major growth booster can be the accelerated number of approvals granted by the FDA that encourages players to focus more on launching new drugs and devices for treating rheumatoid arthritis.

Robust clinical pipeline, supportive reimbursement policies and high healthcare spending across various countries also facilitate market growth. Large-scale pharmaceutical firms are focused on developing innovative products associated with rheumatoid arthritis, while emerging countries are offering opportunities that are grabbing the interest of global companies. These developments in the global market should foster revenue generation in the following years.

Market Segmentation

To offer an extensive outline of the rheumatoid arthritis industry, the MRFR report has listed drug type, diagnosis, and treatment as the key segments.

The drug types considered in the report are steroids, non-steroidal anti-inflammatory drug type (NSAID), and biologic agents. Non-steroidal anti-inflammatory drugs or NSAIDs such as ibuprofen, naproxen and diclofenac are quite effective in reducing the pain. NSAID gels are also used extensively for alleviating the pain since there are lower chances of side effects.

Diagnosis-wise, the major segments include ESR test, CCP, C-Reactive Protein (CRP) Test, and more. CRP tests are highly popular diagnosis types that are not only rapid but also accurate. These easy-to-use tests that can be done in different healthcare settings. Government initiatives encouraging the use of CRP tests in various healthcare settings should also help the segment grow in the coming years.

The key treatment lines available in the market include joint fusion, tendon repair, synovectomy, and others. Joint fusion surgeries have become the most popular treatment line among doctors, and these bring down pain considerably. Therefore, patient satisfaction as well as reduced need for frequent procedures will foster the demand for joint fusion treatment in the next couple of years.

Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/1658

Regional Study

North America and APAC or Asia Pacific along with Europe and MEA or Middle East and Africa are the key regions where the rheumatoid arthritis industry can experience growth during the conjectured period.

North America has secured the lead in the global market since the region accommodates a highly developed healthcare system with a high budget. The RA market in North America is fostered by the rising use of new products in the JAK and IL-6 inhibitor classes combined with the introduction of advanced pipeline therapies. More than 70% of the total sales are reported in the US; as the country as a huge population of patients and significant costs of targeted synthetic disease modifying anti-rheumatic drugs and biologics.

Europe is the second highest gainer in the global market and can potentially attain a significant growth rate in the ensuing years, on account of the increased spending on research activities. Mounting burden of rheumatoid arthritis, subsequent increase in the need for rheumatoid arthritis drugs and the expiration of existing patents and the emergence of biosimilar drugs should benefit the European market over the years ahead. Exploding geriatric pool, rising adoption of DMARDs, and surge in government efforts to bolster the awareness level about for rheumatoid arthritis symptoms will also favor the regional market.

Asia Pacific offers attractive opportunities to global companies and should capture the fastest CAGR in the coming years. With highly populated countries home to vast pools of patients, rise in public awareness about the benefits of the associated drugs and the advances in the R&D field seem to be working in favor of the APAC market. Additionally, surge in healthcare reforms and renowned manufacturers focusing on bolstering their presence in the region will also ensure that the APAC market witnesses better growth in the near future.

Browse Complete Toc :https://www.marketresearchfuture.com/reports/rheumatoid-arthritis-market-1658

Affluent Firms

Affluent companies in the global market for rheumatoid arthritis are Eli Lilly and company (U.S), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company (U.S), Pfizer Inc (U.S), AstraZeneca (U.K), Novartis AG (Switzerland), Vertex Pharmaceuticals Incorporated (U.S), and many more.

Latest Developments

March 2021

Samsung Bioepis (Republic of Korea) has launched adalimumab biosimilar Hadlima in Australia. Hadlima is a biosimilar that helps treat rheumatoid arthritis along with psoriatic arthritis, juvenile idiopathic arthritis, adult and paediatric Crohn’s disease, ankylosing spondylitis, hidradenitis suppurativa, plaque psoriasis and ulcerative colitis.